ChondroFiller is not available on the NHS

The treatment has no NICE health technology appraisal and sits outside every NHS commissioning framework, which means GPs have no referral route into a ChondroFiller pathway on the public system. Every UK patient who receives it does so entirely through private care — either self-funded or via private medical insurance.

For context, autologous chondrocyte implantation (ACI) remains the only cartilage cell therapy the NHS commissions, having received approval in 2017. ChondroFiller is not part of that pathway and has no equivalent approval.

Some patients ask whether an Individual Funding Request (IFR) — an exceptional-case process through which NHS trusts can fund treatments outside standard commissioning — might offer a route. No published precedent for ChondroFiller has been confirmed through that process, so patients should not assume an IFR application would succeed or that such a route is routinely viable.

How much ChondroFiller costs privately in the UK

Pricing is driven by a single clinical variable: how much surface area the cartilage defect covers. Published UK clinic tariffs follow a tiered, per-box model, with each additional box corresponding to a larger defect.

The three main tiers, as set out in currently published tariffs, are:

• One box (covering defects up to approximately 3 cm²): around £3,000
• Two boxes (up to approximately 4.5 cm²): around £5,500
• Three boxes (up to approximately 6 cm²): around £8,000

Complex or multi-compartment cases may attract a higher tier, with some published tariffs extending to approximately £9,800. These figures are all-inclusive outpatient package prices — covering the initial consultation, real-time ultrasound guidance, the implant itself, intravenous antibiotic cover during the procedure, and a six-week follow-up appointment. They are not procedure-only fees.

For most patients presenting with a single focal defect, one box is the typical starting point. The exact volume cannot be confirmed ahead of a pre-treatment MRI, which establishes the lesion's dimensions and, therefore, which tier applies.

No joint-specific premium applies; the same tier structure is used whether the defect is in the knee, hip, ankle, or shoulder.

Published pricing from providers outside major UK cities is limited, so available tariffs should be treated as indicative rather than exhaustive. Figures are subject to change, and individual suitability assessment always determines which tier — and what total cost — applies to a given patient.

What the package price includes

One item sits outside the all-inclusive package described above: the pre-treatment MRI scan. A scan is typically required before any appointment to size the lesion accurately — the result directly determines which pricing tier applies — but it is not usually bundled into the ChondroFiller fee. Patients who do not already hold a recent, suitable MRI should factor that additional cost into their overall budget before the initial consultation.

That distinction becomes important when comparing ChondroFiller's headline figure against the listed price of other intra-articular injections. Many procedures are quoted as a procedure-only fee, with consultation, imaging guidance, and any follow-up appointment each charged separately. Because a ChondroFiller package already covers those elements, a fair comparison means checking what a comparator price actually includes before treating the numerical difference as the true cost gap.

Ultrasound guidance is worth singling out here: it is an integral part of the injection delivery — ensuring the scaffold reaches the defect site precisely — not an elective add-on billed on top of the injection fee. Any injection pathway that uses real-time imaging for placement may carry a similar line item in its own pricing structure.

Why ChondroFiller is priced this way

CE Class III is the highest regulatory risk category for a medical device in Europe — the same band as an implantable cardiac pacemaker. ChondroFiller carries that classification because it is a biologically derived scaffold intended to integrate with living tissue, not a pharmaceutical that is metabolised and cleared. Manufacturing at that standard demands rigorous quality assurance, traceability, and batch testing at every stage of production.

The implant itself is a murine-derived Type I collagen scaffold produced by Meidrix Biomedicals GmbH in Germany and imported into the UK under prescription. Supply-chain and manufacturing costs at this specification level are a primary driver of the overall price — the per-box structure follows directly from that reality. Each additional box represents additional manufactured scaffold volume, not an arbitrary clinical uplift.

Patients who have previously received a hyaluronic acid or corticosteroid injection sometimes compare those prices against ChondroFiller's. The comparison is not like-for-like. Standard intra-articular injectables are off-the-shelf pharmaceuticals, produced at pharmaceutical scale, and priced accordingly. ChondroFiller is an individually sourced biological device, subject to Class III manufacturing controls and imported specifically for each treatment course. The cost difference reflects that distinction in regulatory category and production reality.

Private medical insurance and ChondroFiller

Patients holding private medical insurance should not assume ChondroFiller falls within their policy's standard covered-procedures list. Most PMI policies class it as a non-standard treatment, and automatic coverage is not the norm.

That said, case-by-case pre-authorisation has been reported with a number of major UK insurers — though outcomes vary considerably by policy type, policy year, and the clinical information submitted. The critical step is contacting the insurer directly before booking any appointment and obtaining written pre-authorisation. Insurers will not retrospectively fund a procedure that was not approved in advance; a verbal indication from a call-handler carries no weight at the point of claim.

When approaching an insurer, it helps to confirm the applicable CCSD billing codes with the treating clinician beforehand. Codes covering cartilage scaffold procedures and arthroscopy are used when submitting pre-authorisation requests, though presenting the correct code is the beginning of the process, not a guarantee of approval.

One further caveat worth noting: insurer positions on newer procedures are not fixed. Coverage criteria can shift between annual policy renewals, and anecdotal reports of past approvals — including those circulating in patient forums — may not reflect what a given insurer will authorise today. A patient's own current policy documents and a direct conversation with their insurer's pre-authorisation team remain the most reliable source of truth on what is and is not covered.

Finding out whether you're a suitable candidate

Suitability for ChondroFiller turns on a specific clinical finding: a focal cartilage defect with defined edges and measurable depth, rather than the diffuse cartilage thinning typical of established osteoarthritis. Those two presentations call for different treatment approaches, and ChondroFiller is designed for the former.

The joints where treatment has been applied include the knee, hip, ankle, and shoulder — though suitability varies by joint and by the precise characteristics of the lesion. Defect location, size, and the condition of surrounding cartilage all influence whether the scaffold is appropriate.

These variables cannot be self-assessed. Whether a specific defect falls within the treatment range — and which pricing tier would apply — becomes clear only after imaging and clinical review. For a patient who has already been told they have a cartilage lesion, or who suspects one, a specialist suitability assessment is the natural next step. For someone with widespread joint-space narrowing across multiple compartments, a different treatment pathway is likely to be more appropriate.